January 25, 2017
Novartis 2016 full year net income down 6%
Novartis delivered a solid performance in 2016, absorbing Gleevec US loss of exclusivity while investing in key launches and the Alcon Division turnaround
Pharmaceuticals, Biotechnology and Life Sciences
Category: Europe
January 25, 2017
TXCell needs €11M by issuing new shares, covers next year’s requirements
TxCell has moved into action to raise some money, as it wants to raise gross proceeds of about €11 million by issuing new shares with warrants attached.
January 25, 2017
InnovaDerma misses deal with Korean distributor, seeks new negotiating round
The deal InnovaDerma had with PROS International Company of Korea to sell InnovaDerma products in a terrotiroy of S Korea, Japan, China and Russia has breaken apart, the UK based maker of hair and skin care products said on Wednesday.
January 25, 2017
Biocorp to participate at Pharmapack exhibition 2017
Biocorp, a French company specializing in the development and manufacturing of medical devices and smart drug delivery systems, has announced it will be part of the 20th edition of Pharmapack exhibition, which will take place on 1st-2ndFebruary 2017, in Paris (France).
January 24, 2017
Probi praises Nutraceutix purchase, announces good Q4 results
Probi, Swedish bioengineering company that develops probiotics has reported Q4 2016 financial results.
January 24, 2017
Horizon Discovery expects 2016 revenue up 20%
Horizon Discovery Group expects to see 2016 revenues rise for about 20%, as it expects revenue of at least £24.0 million.
January 24, 2017
Quantum Pharma grantes options to its CFO
Quantum Pharma, has granted options over 1,100,000 Ordinary Shares of 10 pence each (‘Ordinary Shares’) with an exercise price of 30 pence, to Gerard Murray, Chief Financial Officer.
January 24, 2017
Nicox to test new eye drug
Nicox, the international ophthalmic R&D company, has provided certain regulatory and clinical updates for NCX 470, its novel nitric oxide…
January 24, 2017
Asit’s Phase II study of dust allergy treatment shows success
Asit biotech has completed Phase IIa double-blind placebo-controlled clinical study in house dust mite-induced rhinoconjunctivitis.
January 24, 2017
Abzena to issue ordinary shares
Abzena has made application to the London Stock Exchange for the admission of 715,772 new ordinary shares of £0.002 each (‘New Ordinary Shares’) to trading on AIM.